The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 26, 2005
Filed:
Jul. 10, 2000
Carlos Antonio Durate Cano, Habana, CU;
Enrique Gerardo Guillen Nieto, Habana, CU;
Anabel Alvarez Acosta, Habana, CU;
Luis Emilio Carpio Munoz, Sancti Spiritus, CU;
Diogenes Quintana Vazquez, Pinar del Rio, CU;
Carmen Elena Gomez Rodriquez, Habana, CU;
Recardo DE LA Caridid Siva Rodriquez, Habana, CU;
Consuelo Nazabal Galvez, Habana, CU;
Maria DE Jesus Leal Angulo, Habana, CU;
Alejandro Miguel Martin Dunn, Habana, CU;
Carlos Antonio Durate Cano, Habana, CU;
Enrique Gerardo Guillen Nieto, Habana, CU;
Anabel Alvarez Acosta, Habana, CU;
Luis Emilio Carpio Munoz, Sancti Spiritus, CU;
Diogenes Quintana Vazquez, Pinar del Rio, CU;
Carmen Elena Gomez Rodriquez, Habana, CU;
Recardo De La Caridid Siva Rodriquez, Habana, CU;
Consuelo Nazabal Galvez, Habana, CU;
Maria De Jesus Leal Angulo, Habana, CU;
Alejandro Miguel Martin Dunn, Habana, CU;
Abstract
The present invention related to biotechnology and genetic engineering, particularly the expression of proteins of viral origin in microorganisms through their fusion by applying recombinant DNA technology to bacterial peptides. The present invention provides an effcient process for the expression inof heterlogous proteins as fusion peptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an appropriate form for their inclusion in vaccine preparations. What is essentially used is a stabilizing sequence derived from the first 47 amino acids of the antigen P64k ofB:4:P1.15. In particular, use is made of a recombinant plasmid containing said sequence, under the control of the tryptophane promoter ofand of the terminator of the transcription of the phage T4, including restrictions sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest.